Hansa Biopharma AB (publ)
STO: HNSA.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Renee Aguiar-Lucander
- Employees
- 138
- Headquarters
- Lund, Sweden
- IPO year
- 2007
- Market cap
- SEK 2.3B
- Website
- https://www.hansabiopharma.com
Loading HNSA…
Loading profile data…Frequently asked questions about HNSA
What does Hansa Biopharma AB (publ) (HNSA.ST) do?
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that...
Where does HNSA.ST trade?
Hansa Biopharma AB (publ) (HNSA.ST) trades on the Stockholm Stock Exchange.
What sector is HNSA.ST in?
Hansa Biopharma AB (publ) (HNSA.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hansa Biopharma AB (publ)?
Renee Aguiar-Lucander is the chief executive officer of Hansa Biopharma AB (publ) (HNSA.ST).
Where is Hansa Biopharma AB (publ) headquartered?
Hansa Biopharma AB (publ) is headquartered in Sweden.
Does HNSA.ST pay a dividend?
Hansa Biopharma AB (publ) (HNSA.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HNSA.ST go public?
Hansa Biopharma AB (publ) (HNSA.ST) completed its initial public offering in 2007.